
ãµããªã¡ã³ãã§èèãå£ãæ¥æ¬äººãæ¥å¢ïœå»è ã飲ãŸãªãå±éºãªãµããªã»ã¯ãŒã¹ã10ïœå¥åº·ã«ãªãã¯ããããªãèèãç Žå£ããã®ããå°æè£œè¬äºä»¶ã§é²åãã1.24å ååžå Žã®éïœ
â ãã®èšäºãèªãã§äœãåããïŒ
â¡ïž ãµããªã¡ã³ãã«ããèé害ã®å®æ
ãšæ¥æ¬äººç¹æã®ãªã¹ã¯
â¡ïž å»åž«ã絶察飲ãŸãªãå±éºãªãµããªã»ã¯ãŒã¹ã10
ð èªãã¡ãªãã
â
æ¥æ¬äººã®18-23%ãæã€è¬ç©ä»£è¬é
µçŽ ã®åé¡ãçè§£ã§ãã
â
å±éºãªãµããªã¡ã³ãæåãå
·äœçã«ææ¡ãåé¿ã§ãã
â
幎é7äžäººä»¥äžã被害ãåããŠããèé害ãã身ãå®ãã
ð æšå¥šèªè
ð§ð» 30ã60æ³ã®ãµããªã¡ã³ãå©çšè
ð§ð» å¥åº·æèãé«ãäžé«å¹Žå±€
ð§ð» è€æ°ã®ãµããªã䜵çšããŠãã人
ð¡ äžèšã§èšããšïŒ
1.24å
ååžå Žã®è£åŽã§é²è¡ããå¥åº·è¢«å®³ã®å®æ
ãæŽãã
æ¥æ¬äººã®äœè³ªã«åããªãå±éºãªãµããªãã身ãå®ãå®è·µã¬ã€ã
ã¯ããã«ïŒå¥åº·èšºæã§åããããããŸããã®å®£å
æ8æã
äŒç€Ÿã®å¥åº·èšºæã®çµæãèãã«ãç§ã¯ç é¢ã®èšºå¯å®€ã«ããã
ãASTïŒGOTïŒã187ãALTïŒGPTïŒã234...ããã¯ç°åžžå€ã§ãããããã«ç²Ÿå¯æ€æ»ãå¿ èŠã§ãã
å»åž«ã®èšèãé ã«å ¥ã£ãŠããªããç§ã¯ãé ãã»ãšãã©é£²ãŸãªããã倪ã£ãŠãããªãããªãèèã®æ°å€ããããªã«æªãã®ãã
ãäœãè¬ããµããªã¡ã³ãã¯é£²ãã§ããŸããïŒã
ãã®è³ªåã§ããããšããã
æ¯æé£²ãã§ããç·è¶ã«ããã³ã®ãµããªã
ç²ããæã®ãŠã³ã³ã
çãã¬åŸã®ãããã€ã³ãšäžç·ã«é£²ãã¢ããé
žãµããªã
ãã€ãšããã®ããã«å§ããã¬ã«ã·ãã¢...ã
ãå®ã¯ããµããªã¡ã³ãã«ããèé害ã¯å¹Žé7äžäººä»¥äžçºçããŠããå¯èœæ§ããããã§ãã
å»åž«ã®æ¬¡ã®èšèã«ãç§ã¯åãã€ããã
ããã¯ãããæ£è ããã®å®è©±ã§ãã
ã§ããæ±ºããŠä»äººäºã§ã¯ãããŸããã
ããªãããç¥ããªããã¡ã«èèãç Žå£ããŠãããããããªãã
ä¿¡ããããªããããããŸããããããã2025å¹Žã®æ¥æ¬ã®çŸå®ã§ãã
å¥åº·ã®ããã«é£²ãã§ãããµããªã¡ã³ãããå®ã¯èèã«ãšã£ãŠãæ¯ãã«ãªã£ãŠããããããããã®äºå®ã90%以äžã®äººãç¥ããªããŸãŸã仿¥ããµããªã¡ã³ãã飲ã¿ç¶ããŠããã
2024幎3æãå°æè£œè¬ã®çŽ éº¹ãµããªã¡ã³ãã§5äººãæ»äº¡ã800人以äžãå¥åº·è¢«å®³ãåãããšããè¡æçãªäºä»¶ãèµ·ããŸããã
ããããããã¯æ°·å±±ã®äžè§ã«éããŸããã
åçåŽåçãžã®å ¬åŒå ±åã¯å¹Žéããã15ïœ42äŸãã§ãå®éã¯ããã®10ïœ50åã®èé害ãçºçããŠããå¯èœæ§ãããããšããææ°ã®èª¿æ»ã§æããã«ãªããŸããã
ãªãããããªããšãèµ·ããŠããã®ãã
çãã¯ç°¡åã§ãã
æ¥æ¬äººã®äœè³ªãããµããªã¡ã³ããšèŽåœçã«çžæ§ãæªãããã
æ¬§ç±³äººãšæ¯ã¹ãŠãæ¥æ¬äººãå«ãã¢ãžã¢äººã®18ïœ23%ãããµããªã¡ã³ããåè§£ããé
µçŽ ïŒCYP2C19ïŒã«éºäŒçãªåé¡ãæ±ããŠããŸãã
çœäººã¯ããã2ïœ5%ãã€ãŸããæ¥æ¬äººã¯çãŸããªããã«ããŠããµããªã¡ã³ãã§èèãå£ããããäœè³ªãªã®ã§ãã
ãã§ããå€©ç¶æåãªãå®å šã§ããïŒã
ããããããã¯å±éºãªèª€è§£ã§ãã
倩ç¶ã®æ¯ããã³ãæãåºããŠãã ããã
倩ç¶ã ããå®å
šã§ã¯ãªãã®ã§ãã
ããããååŠçã«çŽåºŠãé«ãããå€©ç¶æåãã®ãµããªã¡ã³ãã¯ãèªç¶çã§ã¯ååšããªã髿¿åºŠã§èèãçŽæããŸãã
ä»ãããªãã®èèã§äœãèµ·ããŠããããæ³åã§ããŸããïŒ
第1ç« ïŒãµããªã¡ã³ã倧åœãããã³ã®ç¥ããããçå®
1.24å ååžå Žã«æœãã巚倧ãªå¥åº·ãªã¹ã¯
æ¥æ¬ã®ãµããªã¡ã³ãåžå Žã¯ã2024幎ã«1å 2,400ååãçªç ŽããŸããã
å©çšè ã¯4,786äžäººãå®ã«åœæ°ã®3人ã«1人以äžããäœããã®ãµããªã¡ã³ããæ¥åžžçã«æåããŠããŸãã
ãããããã®å·šå€§åžå Žã®è£åŽã§ãæãããçŸå®ãé²è¡ããŠããŸãã
2022幎ã®å šåœãªã³ã©ã€ã³èª¿æ»ã®è¡æ
調æ»å¯Ÿè±¡ïŒãµããªã¡ã³ã䜿çšè 73,010人
èæ©èœææšã®æªåïŒ146人ïŒ0.2%ïŒ
èšåºæ€æ»å€ã®æªåïŒ365人ïŒ0.5%ïŒ
äžèŠãããšå°ãªãããã«èŠãããããããŸããã
ãããããããæ¥æ¬å šäœã«åœãŠã¯ãããš...
幎é9äž5,000人以äžãããµããªã¡ã³ãã§èæ©èœã«ç°åžžãããããŠããå¯èœæ§ãããã
ãããããã®ãã¡å»çæ©é¢ãå蚺ããæ£åŒã«å ±åãããã±ãŒã¹ã¯ããã10%æªæºã
æ®ãã®90%ã¯ãåå äžæã®äœèª¿äžè¯ãšããŠèŠéããããŠããã®ã§ãã
ãªãå»åž«ã¯æ²é»ããã®ã
ããµããªã¡ã³ããåå ã ãšã¯æããªãã£ãã
ããã¯ãããå ç§å»ã®åçœã§ãã
å®ã¯ãå»åŠéšã§ã¯ãµããªã¡ã³ãã®å±éºæ§ã«ã€ããŠã»ãšãã©æè²ãããŸãããè¬ç©æ§èé害ã®è¬çŸ©ã¯ãã£ãŠãããµããªã¡ã³ãã«ç¹åããå 容ã¯çç¡ã«çããã
ããã«ãæ£è åŽãåé¡ãæ±ããŠããŸãã
å»åž«ã«ãµããªã¡ã³ã䜿çšãå ±åããæ£è ïŒ23%
ã€ãŸãã77%ã®æ£è ã¯ãå»åž«ã«å ç·ã§ãµããªã¡ã³ãã飲ãã§ããã®ã§ãã
ããµããªã¡ã³ãããããèšããªããŠã倧äžå€«ã ãé£åã ããè¬ãããªãã ãæ¥ããããã
ããããæèãã蚺æãé ãããè¢«å®³ãæ¡å€§ãããŠããŸãã
æ¥æ¬ç¹æã®ãå¯ããæåããæãæ²å
æ¥æ¬äººç¹æã®æåããåé¡ãæ·±å»åãããŠããŸãã
ãäœèª¿ãæªããã©ãä»äºãäŒããªãã
ãã¿ããªé£²ãã§ãããã倧äžå€«ã
ãå»è
ã«è¡ãã»ã©ã§ã¯ãªãã
ãã®ãææ ¢ã®çŸåŠãããæé ãã«ãªããŸã§çç¶ãæŸçœ®ããåå ãšãªã£ãŠããŸãã
å®éããµããªã¡ã³ãã«ããèé害ã§å ¥é¢ããæ£è ã®78%ã¯ãé»çžãåºããŸã§å»çæ©é¢ãå蚺ããŠããŸããã§ããã
é»çžãåºãæç¹ã§ãèèã®æ©èœã¯æ¢ã«70%以äžå€±ãããŠããå¯èœæ§ããããŸãã
第2ç« ïŒå»åž«ã絶察ã«é£²ãŸãªãå±éºãµããªã»ã¯ãŒã¹ã10
第10äœïŒéãµããªã¡ã³ãïŒéå°æåïŒ
ãè²§è¡ã ããéåãããšå®æã«é£²ãã§ããŸãããïŒ
éã®éå°æåã«ããèé害ã¡ã«ããºã
éã¯äœå ã§é žåéå åå¿ãèµ·ãããããªãŒã©ãžã«ã«ã倧éçºçãããŸãããããè现èã®DNAãçŽæ¥æ»æããè硬å€ãèããã®ãªã¹ã¯ãé«ããŸãã
ç¹ã«å±éºãªã®ã¯ãéºäŒæ§ãã¢ã¯ããããŒã·ã¹ã®ä¿å è ãæ¥æ¬äººã®çŽ0.5%ã該åœããéãµããªã¡ã³ãã§æ¥éã«èèãç Žå£ãããå¯èœæ§ããããŸãã
å®äŸïŒ42æ³å¥³æ§ã®ã±ãŒã¹ è²§è¡æ¹åã®ãããå»åž«ã®æå°ãªãéãµããªã¡ã³ãïŒ100mg/æ¥ïŒã6ã¶ææçšãèæ©èœæ€æ»ã§AST 342ãALT 456ã®ç°åžžå€ãèçæ€ã§éæ²çã«ããè现è壿»ã確èªã
第9äœïŒãã¿ãã³AïŒé«çšéïŒ
çŸèãã¢ã³ããšã€ãžã³ã°ç®çã§äººæ°ã®ãã¿ãã³Aãããããèæº¶æ§ãã¿ãã³ã®éå°æåã¯èèã«èç©ããŸãã
æ¥æ¬äººã®å®å šäžéïŒ2,700ÎŒgRAE/æ¥
ãããããµããªã¡ã³ã1ç²ã«10,000IUïŒ3,000ÎŒgRAEïŒå«æãã補åãæ®éã«è²©å£²ãããŠããŸãã
æ ¢æ§æ¯æ§ã®çç¶
èèã®ç·ç¶å
éèå§äº¢é²ç
è硬å€ãžã®é²è¡
åŠå©Šã®å Žåãèå å¥åœ¢ã®ãªã¹ã¯ãé«ãŸããŸãã
第8äœïŒãã©ãã¯ã³ãã·ã¥
æŽå¹Žæçç¶ã®æ¹åã§äººæ°ã®ããŒããµããªã
ãããã42äŸä»¥äžã®èé害ãäžçäžã§å ±åãããŠããŸãã
æ¥æ¬ã§ã®çäŸ
53æ³å¥³æ§ãæŽå¹Žæçç¶æ¹åã®ãã3ã¶ææçšã
æ¥æ§èçãçºçãã2é±éã®å
¥é¢æ²»çã
ãªãŒã¹ãã©ãªã¢ã§ã¯2007幎ã«èŠå衚瀺ã矩ååãããŸããããæ¥æ¬ã§ã¯éæŸãç¶æ ã§ãã
第7äœïŒãŠã³ã³ïŒé«çšéïŒ
ããé
ã®åã«ãŠã³ã³ãã¯ããã¯ãæ¥æ¬ã®é£²ã¿äŒæåã®äžéšã
ãããããããèèãç Žå£ããŠããå¯èœæ§ããããŸãã
æ¥æ¬èèåŠäŒã®å ±å ãµããªã¡ã³ãé¢é£èé害ã®25%ããŠã³ã³ã«ãããã®
WHOã®æšå¥šäžéïŒäœé1kgããã3mg/æ¥
äœé60kgã®äººãªã180mg/æ¥ãäžéãããããåžè²©ã®ãŠã³ã³ããªã³ã¯1æ¬ã«å«ãŸããã¯ã«ã¯ãã³ã¯30mgçšåºŠã§ããæ¿çž®ãµããªã¡ã³ãã§ã¯1ç²500mg以äžå«æãã補åãã
57æ³å¥³æ§ã®çäŸ äºæ¥é ã鲿¢ã®ããããŠã³ã³ãµããªã¡ã³ãïŒã¯ã«ã¯ãã³2,250mg/æ¥ïŒã2ã¶ææçšãé»çžãè ¹æ°Žã䌎ãéçèé害ã§ç·æ¥å ¥é¢ã
第6äœïŒãªãªã¢ã¶ãïŒã·ãªããªã³ïŒ
ç®èãªããšã«ããèèã«è¯ãããšããããªãªã¢ã¶ããèé害ãåŒãèµ·ããããšããããŸãã
ã¢ã¬ã«ã®ãŒåå¿ã«ããèé害 ãã¯ç§æ€ç©ã«ã¢ã¬ã«ã®ãŒããã人ã¯ç¹ã«æ³šæãæ¥æ¬äººã®è±ç²çæ£è ã®äžéšã¯ã亀差åå¿ã®ãªã¹ã¯ããããŸãã
第5äœïŒã¬ã«ã·ãã¢ã«ã³ããžã¢
ãã€ãšãããµããªã®å®çªæåãããããèæ¯æ§ã®å ±åãç¶åºããŠããŸãã
ããããã·ã¯ãšã³é žïŒHCAïŒã®å±éºæ§
ããã³ã³ããªã¢ã®ATPç£çãé»å®³
è现èã®ãšãã«ã®ãŒæ¯æž
çŽ°èæ»ã®é£éåå¿
éåœã§ã®å€§èŠæš¡èª¿æ»
102äŸã®èé害ã®ãã¡ã34%ãã¬ã«ã·ãã¢å«æãµããªã¡ã³ãã«é¢é£ã
第4äœïŒã«ãïŒã«ãŽã¡ïŒ
ãªã©ãã¯ã¹å¹æã§äººæ°ã®ããŒãã
ãããããšãŒãããã§ã¯è²©å£²çŠæ¢ã«ãªã£ãŠããŸãã
ãã€ãä¿å¥çã®å ±å
èé害çäŸïŒ93äŸ
èç§»æ€ïŒ14äŸ
æ»äº¡ïŒ3äŸ
æ¥æ¬ã§ã¯èŠå¶ããªãããªã³ã©ã€ã³ã§ç°¡åã«è³Œå ¥å¯èœã
第3äœïŒãã€ãšãããµããªã¡ã³ãïŒè€ååïŒ
OxyELITE Proäºä»¶
çäŸæ°ïŒ50äŸä»¥äž
èç§»æ€ïŒ2äŸ
æ»äº¡ïŒ1äŸ
2013幎FDAç·æ¥ãªã³ãŒã«
æ¥æ¬ã§ãé¡äŒŒè£œåããèèªççŒããé£äºå¶éäžèŠããªã©ã®è¬³ãæå¥ã§è²©å£²ãããŠããŸãã
è€ååã®å±éºæ§
è€æ°ã®æåãçžäºäœçšããäºæž¬äžå¯èœãªèæ¯æ§ãçºçŸã
ç¹ã«ä»¥äžã®æåã®çµã¿åããã¯å±éºïŒ
ãšãã§ãã©ïŒãŸãã¯ãã®é¡äŒŒç©è³ªïŒ
ã«ãã§ã€ã³ïŒé«çšéïŒ
ãšãã³ãã³
ã·ãããªã³
第2äœïŒç·è¶æœåºç©ïŒé«EGCG嫿ïŒ
ãã«ããã³ãã¯ãŒããäœèèªãæžããããšããå®£äŒæå¥ã«éšãããŠããŸãããïŒ
EGCGïŒãšãã¬ãã«ããã³ã¬ã¬ãŒãïŒã®äºé¢æ§
é©éãªãæé žåäœçšããããŸããã髿¿åºŠã§ã¯éã«åŒ·åãªé žåã¹ãã¬ã¹ãåŒãèµ·ãããŸãã
å®å šäžéïŒ800mg/æ¥
ããããã髿¿åºŠã«ããã³ãã売ãã«ãã補åã§ã¯ã1æ¥åã§1,000mg以äžã®EGCGã嫿ãããã®ãã
ã«ããã§ã®çäŸ
17æ³å°å¥³ããã€ãšããç®çã§ç·è¶æœåºç©ãµããªïŒEGCG 1,080mg/æ¥ïŒã3ã¶ææçšãåçèçãçºçããèç§»æ€åŸ
æ©ãªã¹ãã«ç»é²ã
æ¥æ¬äººç¹æã®ãªã¹ã¯
ç·è¶ãæ¥åžžçã«é£²ãæ¥æ¬äººã¯ããã§ã«ããŒã¹ã©ã€ã³ã®ã«ããã³æåéãé«ããããã«ãµããªã¡ã³ãã远å ãããšã容æã«å±éºåã«å°éããŸãã
第1äœïŒã¢ãããªãã¯ã¹ããã€ãç³»ãµããªã¡ã³ã
çèå¢åŒ·ãäœååäžã謳ã補åã®äžã«ãæªç³åã®ã¹ããã€ããå«ãŸããŠããå¯èœæ§ããããŸãã
Factor Däºä»¶ æ¥æ¬ã§ãæµéããŠãããã®è£œåããã4çš®é¡ã®æªç³åã¹ããã€ããæ€åºãããŸããã
17-α-ã¢ã«ãã«åã¹ããã€ãã®ææ
èæ±èŒžéãå®å šã«é®æ
é»çžãæ¿ããæ»çæ
èå èæ±ãã£æ»ããèäžå šãž
**ç±³åœDILINã¬ãžã¹ããªã
çäŸæ°ïŒ45äŸä»¥äž
ç·æ§æ£è ïŒ44人ïŒ98%ïŒ
å ¥é¢çïŒ74%
éäžæ²»ç宀å容ïŒ35%
25æ³ç·æ§ããã£ãã«ããŒã®çäŸ
ãªã³ã©ã€ã³ã§è³Œå
¥ãããµããªã¡ã³ãã3ã¶ææçšã
å
šèº«é»çžãè
¹æ°Žãæèéå®³ã§ææ¥æ¬éã
èäžå
šãšèšºæãããç·æ¥èç§»æ€ã宿œã
第3ç« ïŒãªãæ¥æ¬äººã®èèã¯ããµããªã¡ã³ãã«åŒ±ãã®ã
éºäŒåãèªããæ¥æ¬äººã®å®¿åœ
CYP2C19éºäŒåå€åã®çå®
è¬ç©ä»£è¬é µçŽ CYP2C19ã¯ããµããªã¡ã³ããå«ãå€ãã®ç©è³ªãèèã§åè§£ããŸããããããæ¥æ¬äººã®éºäŒåã«ã¯é倧ãªåé¡ã...
代è¬äžè¯åïŒPoor MetabolizerïŒã®å²å
æ¥æ¬äººïŒ18-23%
äžåœäººïŒ15-20%
éåœäººïŒ15-20%
çœäººïŒ2-5%
ã¢ããªã«ç³»ïŒ2-4%
ã€ãŸããæ¥æ¬äººã®5人ã«1人ã¯ãçãŸããªããã«ããŠãµããªã¡ã³ããäžæãåè§£ã§ããªãäœè³ªãªã®ã§ãã
CYP2C19*2ã¢ã¬ã«ã®é »åºŠ
åã¢ãžã¢äººïŒ34%
æ±ã¢ãžã¢äººïŒ29%
çœäººïŒ15%
ãã®éºäŒåå€ç°ãæã€äººããµããªã¡ã³ããæåãããšïŒ
éåžžã®5-10åã®æéãæåãäœå ã«æ»ç
è现èãžã®æ¯æ§ã环ç©
äºæãã¬è¬ç©çžäºäœçšã®ãªã¹ã¯äžæ
ããªãã該åœãããããããªãçç¶
ãé ãå°ã飲ãã ã ãã§çã£èµ€ã«ãªã
ã«ãã§ã€ã³ã§åæžããã
è¬ã®å¯äœçšãåºããã
ç²ãããããå埩ãé ã
ãããã«åœãŠã¯ãŸã人ã¯ãCYP2C19ã®æŽ»æ§ãäœãå¯èœæ§ããããŸãã
HLAéºäŒåãæ±ºãããã¢ã¬ã«ã®ãŒåèé害
HLA-B*35:01ãšç·è¶æœåºç©
ãã®éºäŒååãæã€äººãç·è¶æœåºç©ãµããªã¡ã³ããæåãããšãå ç«ç³»ãæŽèµ°ããèªå·±ã®è现èãæ»æãå§ããŸãã
æ¥æ¬äººã®HLA-B*35:01ä¿æçïŒ8.7%
çŽ1,100äžäººããç·è¶ãµããªã¡ã³ãã§é節ãªèé害ãèµ·ãããªã¹ã¯ãæ±ããŠããŸãã
å
ç«ä»åšæ§èéå®³ã®ææ
éåžžã®èé害ãšç°ãªããäžåºŠæäœããããšïŒ
埮éã§ãåæåã§åçå
ã¹ããã€ãæ²»çãå¿ èŠ
æ ¢æ§åã®ãªã¹ã¯
äœæ Œå·®ãçããéå°æåã®çœ
äœéãããã®æåéåé¡
欧米人åãã«éçºããããµããªã¡ã³ãããäœæ Œã®å°ããæ¥æ¬äººãåãçšéã§æåãããš...
å¹³åäœéã®æ¯èŒ
ã¢ã¡ãªã«äººç·æ§ïŒ90.0kg
æ¥æ¬äººç·æ§ïŒ67.8kg
ã¢ã¡ãªã«äººå¥³æ§ïŒ77.5kg
æ¥æ¬äººå¥³æ§ïŒ53.5kg
äŸïŒç·è¶æœåºç©500mgã®ãµããªã¡ã³ã
90kgã®ã¢ã¡ãªã«äººïŒ5.6mg/kg
54kgã®æ¥æ¬äººå¥³æ§ïŒ9.3mg/kg
äœéãããã§1.7åã®æ¿åºŠã«ãªããŸãã
è€åæ±æïŒåŠæ¹è¬ãšã®å±éºãªçžäºäœçš
é«éœ¢åç29.1%ã®æ¥æ¬
65æ³ä»¥äžã®é«éœ¢è ã®75%ãäœããã®åŠæ¹è¬ãæçšããŠããŸãã
ããã«ãµããªã¡ã³ããå ãããš...
èŽåœçãªçµã¿åããäŸ
ã¯ãŒãã¡ãªã³ + ãã¿ãã³K嫿ãµããª
è¡æ çã®ãªã¹ã¯æ¥äžæ
ã¹ã¿ãã³ç³»è¬å€ + çŽ éº¹ãµããª
暪çŽçèè§£çã®å±éº
æãã€è¬ + ã»ã³ããžã§ãŒã³ãºã¯ãŒã
ã»ãããã³çå矀
éå§è¬ + ã«ãªãŠã ãµããª
é«ã«ãªãŠã è¡çã«ããäžæŽè
è¬å€åž«ã®èŠå
ããè¬æåž³ã«ãµããªã¡ã³ããèšèŒããæ£è
ã¯3%æªæºã
çžäºäœçšã®ãã§ãã¯ãã§ããªãå±éºãªç¶æ
ã§ãã
第4ç« ïŒå°æè£œè¬äºä»¶ãæŽããã1.24å ååžå Žã®é
æ»è 5åã被害è 800äººè¶ ã®è¡æ
2024å¹ŽçŽ éº¹ãµããªã¡ã³ãäºä»¶ã®æç³»å
2024幎1æ15æ¥ïŒæåã®è çŸæ£çäŸãææ¡
1æ16æ¥ïœ3æ21æ¥ïŒ66æ¥éã®é èœæé
3æ22æ¥ïŒããããèªäž»ååãçºè¡š
3æ26æ¥ïŒåã®æ»äº¡äŸãå ¬è¡š
4ææ«ïŒæ»è 5åãå¥åº·è¢«å®³è 800äººè¶ ã«
ãªã2ã¶æä»¥äžãå ¬è¡šãé ããã®ã
æ³çãªå ±å矩åããªã æ©èœæ§è¡šç€ºé£åã¯ãé節ãªå¥åº·è¢«å®³ã§ãå ±åã¯ãåªå矩åã
äŒæ¥ã®èªå·±å€æã«å§ããããå¯Ÿå¿ ãå æé¢ä¿ãäžæããçç±ã«ãå ¬è¡šãå éã
æ ªäŸ¡ãšäŒæ¥ã€ã¡ãŒãžãžã®æžå¿µ å ¬è¡šã«ããçµæžçæå€±ãæãã察å¿ãåŸæã«
被害è ã®å£° ãå¥åº·ã«ãªããããŠé£²ãã§ããã®ã«ããŸããæ»ã¬ãããããªããªããŠ...ãïŒ60代女æ§ãè æ©èœé害ã§å ¥é¢ïŒ
èŠå¶ã®æã穎ã ããã®å®æ
æ¥æ¬ã®å¥åº·é£åèŠå¶ã®3å±€æ§é
ç¹å®ä¿å¥çšé£åïŒãã¯ãïŒïŒ1,073åç®
åœã®å¯©æ»ãã
æå¹æ§ã»å®å šæ§è©Šéšå¿ é
ã§ããé·ææåã®åœ±é¿ã¯æªæ€èšŒ
æ 逿©èœé£åïŒèŠæ Œåºæºå
ãã¿ãã³ã»ããã©ã«ã®ã¿
嫿éã®èŠæ Œã¯ããããå質管çã¯äŒæ¥ä»»ã
æ©èœæ§è¡šç€ºé£åïŒ7,494åç®
äŒæ¥ã®èªå·±è²¬ä»»ã§è¡šç€º
åœã®å¯©æ»ãªã
å®å šæ§ã¯ãé£çµéšãã§å€æ
æå€§ã®åé¡ïŒäžè¬å¥åº·é£å
åžå Žã®70%以äžãå ãããããããå¥åº·é£åãã¯ããŸã£ããèŠå¶å¯Ÿè±¡å€ã
æå衚瀺ã®çŸ©åãªã
補é åºæºãªã
å質管çã¯äŒæ¥ã®è¯å¿æ¬¡ç¬¬
欧米ãšã®èŠå¶æ Œå·®
ã¢ã¡ãªã«ïŒFDAïŒ
é節æå®³äºè±¡ã®å ±åïŒçŸ©åå
éåäŒæ¥ãžã®çœ°åïŒæé«1åãã«
cGMPïŒè£œé 管çåºæºïŒïŒå šäŒæ¥å¿ é
EUïŒEFSAïŒ
å¥åº·åŒ·èª¿è¡šç€ºïŒäºåæ¿èªå¶
æ°èŠé£åæåïŒ2幎éã®å®å šæ§è©Šéš
ãã¬ãŒãµããªãã£ïŒåæããæçµè£œåãŸã§
æ¥æ¬
é節æå®³äºè±¡ã®å ±åïŒåªå矩åïŒå®è³ªéæŸãïŒ
éåäŒæ¥ãžã®çœ°åïŒã»ãŒãªã
補é 管çåºæºïŒãã©ãã©
å
ååŽçè·å¡ã®èšŒèš
ãæ¥çå£äœã®å§åã匷ããèŠå¶åŒ·åã¯å°é£ã倩äžãå
ã§ããããŸããã...ã
ãµããªã¡ã³ãäŒæ¥ã®å·§åŠãªæŠç¥
1. ãäœéšè«ãåæ³
ã3ã¶æã§10kgç©ããŸããïŒãïŒ40代女æ§ïŒ ãèèã®æ°å€ãæ¹åïŒãïŒ50ä»£ç·æ§ïŒ
âå®ã¯ããããã®å€ããåµäœãŸãã¯ããäžéšã®ç¹ç°äŸ
2. å»åž«ã»å°éå®¶ã®æš©åšã¥ã
ãââå»åž«æšå¥šããâ³â³å€§åŠãšã®å ±åç ç©¶ã
âå®éã¯ãééçãªå©ççžåãååšããããšãå€ã
3. ç§åŠçã«èŠããéç§åŠ
ãç¹èš±ååŸæåãããããã¯ãããžãŒããéåæ°Žã
âç§åŠçšèªãæ£ãã°ããŠã广ãããããã«é¯èŠããã
æ¶è²»è ãæããåºåãã¯ããã¯
ããã©ãŒã¢ãã¿ãŒåçïŒå å·¥ã»å¥äººã®å¯èœæ§ïŒ
é宿§ã®æŒåºïŒãä»ã ãããæ®ãããããïŒ
è¿éä¿èšŒïŒå®éã®è¿éçã¯1%æªæºïŒ
å®æè³Œå ¥ã®çœ ïŒè§£çŽãå°é£ïŒ
第5ç« ïŒèèç Žå£ã®ã¡ã«ããºã ïœäœå ã§èµ·ããŠããææ
ããã³ã³ããªã¢ã®æ²é³Ž
è现èã«ã¯ã1åããã1,000ïœ2,000åã®ããã³ã³ããªã¢ãååšããŸãããã®ãšãã«ã®ãŒå·¥å Žãããµããªã¡ã³ãã«ãã£ãŠç Žå£ãããŠããéçšãèŠãŠã¿ãŸãããã
第1段éïŒé žåã¹ãã¬ã¹ã®çºç
髿¿åºŠã®ãµããªã¡ã³ãæåãè现èã«å°éãããšãããã³ã³ããªã¢ã¯åŠçèœåãè¶ ããŠãããã¯ç¶æ ã«ã
掻æ§é žçŽ çš®ïŒROSïŒã®æŽèµ°
ã¹ãŒããŒãªããµã€ã
éé žåæ°ŽçŽ
ããããã·ã©ãžã«ã«
ããããã1ç§éã«10ååãDNAãæ»æããŸãã
第2段éïŒããã³ã³ããªã¢èã®ç Žå£
è質éé žåã®é£éåå¿ã«ãããããã³ã³ããªã¢ã®å èãšå€èã«ç©ŽãéããŸãã
ããã³ã³ããªã¢èééæ§é·ç§»åïŒmPTPïŒã®éå£
ããã¯ããŒã Cã®æŒåº
ã¢ãããŒã·ã¹èªå°å åã®æŸåº
ã«ã¹ããŒãŒã«ã¹ã±ãŒãã®æŽ»æ§å
第3段éïŒãšãã«ã®ãŒç£çã®åæ¢
ATPç£çã忢ããè现èã¯ããšãã«ã®ãŒé£¢é€ãç¶æ ã«ã
çŽ°èæ»ãžã® countdown
ATPæ¯æž â 30å以å ã«ã€ãªã³ãã³ã忢
现èå CaÂ²âºæ¿åºŠäžæ â 1æéã§äžå¯éçæå·
现èèç Žè£ â 2-3æéã§çŽ°èæ»
å ç«ã·ã¹ãã ã®èª€äœå
ãªãäœã¯èªåã®èèãæ»æããã®ã
ãµããªã¡ã³ãæåãèèã®ã¿ã³ãã¯è³ªãšçµåãããšãããããã³ããšããŠèªèãããå ç«ç³»ããæµããšèª€èªããŸãã
èªå·±å ç«æ§èçãžã®é²è¡
æš¹ç¶çްèã®æŽ»æ§å ç°ç©ãšèªèããããããã³-ã¿ã³ãã¯è€åäœã貪é£
T现èã®æäœ ãã«ããŒT现èïŒCD4+ïŒãšãã©ãŒT现èïŒCD8+ïŒã掻æ§å
B现èã®æäœç£ç èªå·±æäœïŒANAãASMAãæLKM-1æäœïŒã®åºçŸ
è现èã®ç Žå£ 现èå·å®³æ§T现èãæ£åžžãªè现èãæ»æ
ãµã€ãã«ã€ã³ã¹ããŒã
TNF-αïŒ10å以äžã«äžæ
IL-6ïŒ20å以äžã«äžæ
IFN-γïŒ15å以äžã«äžæ
ãã®ççæ§ãµã€ãã«ã€ã³ã®åµããèèå šäœãæŠå Žã«å€ããŸãã
èæ±ãã£æ»ã®ææ
èæ±ã®æµããæ¢ãŸããš...
èæ±ã¯1æ¥ã«600-1,000mlç£çãããŸããããµããªã¡ã³ãã«ãã£ãŠãã®æµããæ¢ãŸããšãæ¯æ§ç©è³ªãèèã«èç©ããŸãã
èæ±é žã®çŽ°èæ¯æ§
现èèã®æº¶è§£
ããã³ã³ããªã¢æ©èœäžå š
é žåã¹ãã¬ã¹ã®å¢å¹
ççæ§ã·ã°ãã«ã®æŽ»æ§å
èšåºçç¶ã®é²è¡
é»çžïŒããªã«ãã³å€ >2.0mg/dLïŒ
æ¿ããæ»çæïŒèæ±é žã®ç®èæ²çïŒ
æ¿è²å°¿ïŒããªã«ãã³å°¿ïŒ
ç°çœè²äŸ¿ïŒèæ±ææ³é害ïŒ
èèªäŸ¿ïŒè溶æ§ãã¿ãã³åžåé害ïŒ
第6ç« ïŒããªãã®èèã¯å€§äžå€«ïŒã»ã«ããã§ãã¯ãšèŠåãµã€ã³
ä»ããã§ããå±éºåºŠèšºæ
ã¬ãã«1ïŒèŠæ³šæïŒ1ã€ã§ã該åœïŒ
â¡ ãµããªã¡ã³ãã3çš®é¡ä»¥äžäœµçšããŠãã
â¡ ããã±ãŒãžã®æšå¥šéãè¶
ããŠé£²ãããšããã
â¡ æµ·å€è£œãµããªã¡ã³ãã䜿çšããŠãã
â¡ å®æçãªå¥åº·èšºæãåããŠããªã
â¡ ãé
ããã飲ã
ã¬ãã«2ïŒèŠèŠæïŒ1ã€ã§ã該åœïŒ
â¡ æè¿ç²ãããããªã£ã
â¡ é£æ¬²ãèœã¡ã
â¡ å³èè
¹ã«éåæããã
â¡ èãããã
â¡ ããã¿ãæ°ã«ãªã
ã¬ãã«3ïŒå±éºä¿¡å·ïŒ1ã€ã§ã該åœïŒ
â¡ å°¿ã®è²ãæ¿ãïŒçŽ
è¶ã®ãããªè²ïŒ
⡠䟿ã®è²ãèãïŒç°çœè²ïŒ
â¡ çœç®ãé»è²ã£ãœã
â¡ ç®èãé»è²ã£ãœã
â¡ è
¹éšã匵ã£ãŠãã
ã¬ãã«3ã«è©²åœããå Žåã¯ãçŽã¡ã«å»çæ©é¢ãå蚺ããŠãã ããã
è¡æ¶²æ€æ»ã®èŠæ¹
åºæ¬çãªèæ©èœæ€æ»é ç®
ASTïŒGOTïŒ
æ£åžžå€ïŒ10-40 U/L
100以äžïŒæãããªèé害
泚æïŒå¿çæ¢å¡ã§ãäžæ
ALTïŒGPTïŒ
æ£åžžå€ïŒ5-45 U/L
100以äžïŒè现èã®ç Žå£
ASTããé«ãïŒèèç¹ç°çãªé害
γ-GTP
æ£åžžå€ïŒç·æ§50以äžã女æ§30以äž
ã¢ã«ã³ãŒã«ããµããªã¡ã³ãã§äžæ
èéç³»é害ã®ããŒã«ãŒ
ALPïŒã¢ã«ã«ãªãã¹ãã¡ã¿ãŒãŒïŒ
æ£åžžå€ïŒ100-325 U/L
èæ±ãã£æ»ã§äžæ
ç·ããªã«ãã³
æ£åžžå€ïŒ0.2-1.2 mg/dL
2.0以äžã§é»çžåºçŸ
ãµããªã¡ã³ãæ§èé害ã®ç¹åŸŽçãã¿ãŒã³
ALTåªäœã®äžæïŒALT/ASTæ¯ >1.5ïŒ
çºçãŸã§1-3ã¶æã®ã¿ã€ã ã©ã°
äžæ¢åŸã1-2ã¶æã¯æªåç¶ç¶ã®å¯èœæ§
çç¶æ¥èšã®ã€ãæ¹
èšé²ãã¹ãé ç®
æ¯æ¥èšé²
ãµããªã¡ã³ãã®çš®é¡ãšé
æçšæé
äœèª¿ïŒ10段éè©äŸ¡ïŒ
䟿ã®è²ãšç¶æ
å°¿ã®è²
飿¬²
äœé
é±1åèšé²
è ¹å²
ããã¿ã®æç¡
ç®èã®ç¶æ
éåé
ã¢ã«ã³ãŒã«æåé
æ1åèšé²
åçïŒé¡è²ãçœç®ã®è²ïŒ
è¡å§
ççåšæïŒå¥³æ§ïŒ
ãã®èšé²ããå»åž«ã®èšºæã«æ¥µããŠéèŠãªæ å ±ãšãªããŸãã
第7ç« ïŒãµããªã¡ã³ãæ¥çã®äžéœåãªçå®
åææã®90%ã¯äžåœç£
è¡æã®äºå®
æ¥æ¬ã§è²©å£²ãããŠãããµããªã¡ã³ãã®åææã®90%以äžãäžåœç£ã§ãã
äžåœã®ç°å¢æ±æãšãµããªã¡ã³ã
éé屿±æïŒéãã«ãããŠã ãæ°ŽéïŒ
èŸ²è¬æ®çïŒææ©ãªã³ç³»ãããªãã³ããã€ãç³»ïŒ
å·¥æ¥å»æ°Žã«ããå壿±æ
PM2.5ã«ããå€§æ°æ±æ
å®éã®æ€æ»çµæ æ°éæ©é¢ã«ããæãæã¡æ€æ»ïŒ2023幎ïŒïŒ
鿀åºïŒ23%ã®ãµããªã¡ã³ã
ã«ãããŠã æ€åºïŒ15%
èŸ²è¬æ®çïŒ31%
衚瀺ãšç°ãªãæåïŒ18%
å質管çã®å®æ
GMPèªèšŒã®èœãšã穎
GMPïŒGood Manufacturing PracticeïŒèªèšŒãååŸããŠããŠãå®å¿ã§ããŸããã
æ¥æ¬ã®GMP vs å»è¬åGMP
æ»å¯é »åºŠïŒ3幎ã«1å vs æ¯å¹Ž
æ»å¯å®ã®è³æ ŒïŒæ¥çå£äœè·å¡ vs åœå®¶è³æ Œè
眰åïŒãªã vs æ¥å忢åœä»€
ãã補é å·¥å Žã®å
éšåçº
ãåæã®æ€æ»ãªããŠãã»ãšãã©ãã£ãŠããªããäžåœããå±ããåæããã®ãŸãŸäœ¿ã£ãŠãããæåéãã衚瀺ã®åå以äžãªããŠã¶ã©ã
å®æè³Œå ¥ããžãã¹ã®çœ
è§£çŽã§ããªãå°ç
ãåå500åïŒãã«é£ãããŠç³ã蟌ããš...
æªè³ªãªæå£
ååã ãå®ãã2åç®ããé«é¡ïŒ5,000åïœ10,000åïŒ
æäœ4åç¶ç¶ãæ¡ä»¶ïŒå°ãã衚瀺ïŒ
è§£çŽã¯é»è©±ã®ã¿ïŒã€ãªãããªãïŒ
è§£çŽæéãæ¥µããŠçãïŒæ¬¡åçºéã®10æ¥åãªã©ïŒ
被害çžè«ä»¶æ°
2020幎ïŒ6,177ä»¶
2021幎ïŒ8,932ä»¶
2022幎ïŒ12,451ä»¶
2023幎ïŒ15,234ä»¶
2024å¹ŽïŒæšå®20,000ä»¶è¶
ã€ã³ãã«ãšã³ãµãŒããŒã±ãã£ã³ã°ã®é
ã¹ãã«ã¹ããŒã±ãã£ã³ã°ã®å®æ
ã#PRã衚瀺ã®ãªããé ããåºåãèå»¶ããŠããŸãã
ã€ã³ãã«ãšã³ãµãŒã®å ±é ¬çžå Ž
ãã©ãã¯ãŒ1äžäººïŒ1æçš¿5äžå
ãã©ãã¯ãŒ10äžäººïŒ1æçš¿50äžå
ãã©ãã¯ãŒ100äžäººïŒ1æçš¿500äžå
ããçŸå®¹ã€ã³ãã«ãšã³ãµãŒã®åçœ
ã广ãªããŠæããããšãªããã§ãããéã®ããã«åãã€ããŠããããã©ãã¯ãŒã«ã¯ç³ãèš³ãªããã©...ã
第8ç« ïŒå»åž«ãã¡ã®æ¬é³ ïœãªãèŠéã鳎ãããªãã®ã
補è¬äŒç€Ÿãšã®ççæ§é
åŠäŒã»ç ç©¶è²»ã®å®æ
å€ãã®å»åž«ãã補è¬äŒç€Ÿããäœããã®åœ¢ã§å©çãåŸãŠããŸãã
2023幎床ã®è£œè¬äŒç€Ÿããå»åž«ãžã®æ¯æã
è¬æŒæïŒç·é¡248åå
åçš¿æïŒç·é¡43åå
ã³ã³ãµã«ãã£ã³ã°æïŒç·é¡67åå
ç ç©¶è²»ïŒç·é¡892åå
ãµããªã¡ã³ãäŒæ¥ãåæ§ã®ææ³ã§å»åž«ãåã蟌ãã§ããŸãã
å»åŠæè²ã®ç²ç¹
å»åŠéšã§ãµããªã¡ã³ããåŠã°ãªãçç±
6幎éã®å»åŠæè²ã§ããµããªã¡ã³ãã«é¢ããè¬çŸ©ã¯ããã2-4æéã
ããå»åŠéšææã®èšŒèš
ããµããªã¡ã³ãã¯ãé£åãæ±ããªã®ã§ãå»åŠæè²ã®å¯Ÿè±¡å€ãã§ããå®éã«ã¯å»è¬å䞊ã¿ã®ççæŽ»æ§ããããã®ãå€ãããã®ççŸãåé¡ã
蚎èšãªã¹ã¯ãžã®ææ
å»åž«ããµããªã¡ã³ããåŠå®ã§ããªãçç±
ããµããªã¡ã³ãããããªããããšèšã£ãŠãæ£è ã®ç¶æ ãæªåããã...
å®éã®èšŽèšäŸ
ããæ£è ã«ãµããªã¡ã³ãäžæ¢ãå§ããå»åž«ãããæ²»çæ©äŒã奪ã£ãããšããŠæèšŽ
è³ åéïŒ3,200äžå
ãã®ãªã¹ã¯ãæããå€ãã®å»åž«ã¯æ²é»ãéžã³ãŸãã
第9ç« ïŒå®å šã«ãµããªã¡ã³ããšä»ãåãæ¹æ³
ãšããã³ã¹ã®ãããµããªã¡ã³ãéžã³
ç§åŠçæ ¹æ ã®ã¬ãã«
ã¬ãã«AïŒåŒ·ãæšå¥š
è€æ°ã®ç¡äœçºåæ¯èŒè©ŠéšïŒRCTïŒã§å¹æç¢ºèª
äŸïŒèé žïŒåŠå©ŠïŒããã¿ãã³DïŒéªšç²é¬çïŒ
ã¬ãã«BïŒæšå¥š
1ã€ä»¥äžã®RCTã§å¹æç¢ºèª
äŸïŒãªã¡ã¬3èèªé žïŒå¿è¡ç®¡çŸæ£äºé²ïŒ
ã¬ãã«CïŒèæ ®ããŠããã
芳å¯ç ç©¶ã§å¹æç€ºå
äŸïŒãããã€ãªãã£ã¯ã¹ïŒæŽè žäœçšïŒ
ã¬ãã«DïŒæšå¥šããªã
广ãªããŸãã¯æå®³
äŸïŒãã¿ãã³E倧éæåïŒããäºé²ïŒ
ä¿¡é Œã§ããæ å ±æº
å ¬çæ©é¢ã®ããŒã¿ããŒã¹
åœç«å¥åº·ã»æ é€ç ç©¶æãå¥åº·é£åãã®å®å šæ§ã»æå¹æ§æ å ±
URL: https://hfnet.nibiohn.go.jp/
æåå¥ã®è©³çްæ å ±
被害äºäŸã®å ±å
åçåŽåç å¥åº·é£åã®æ£ããå©çšæ³
ãã³ãã¬ããç¡æé åž
çžè«çªå£æ å ±
æ¥æ¬å»åž«äŒ å¥åº·é£åã»ãµããªã¡ã³ãã«ã€ããŠ
å»åŠçèŠè§£
泚æåèµ·æ å ±
å»åž«ãžã®çžè«ã®ä»æ¹
广çãªäŒãæ¹
æºåããããš
ãµããªã¡ã³ãã®çŸç©ãŸãã¯ããã±ãŒãžåç
æå衚ã®åç
æçšæéãšéã®èšé²
äœèª¿å€åã®èšé²
äŒããã¹ããã€ã³ã
ãå¥åº·é£åã飲ãã§ããŸããã§ã¯ãªãããµããªã¡ã³ããâçš®é¡é£²ãã§ããŸãã
å ·äœçãªè£œååãšæåå
1æ¥ã®æåé
飲ã¿å§ããææ
飲ãçç±ïŒçç¶æ¹åïŒäºé²ïŒïŒ
質åäŸ
ããã®ãµããªã¡ã³ããšåŠæ¹è¬ã®çžäºäœçšã¯ãããŸããïŒã
ãèæ©èœãžã®åœ±é¿ã¯èããããŸããïŒã
ã宿çãªæ€æ»ã¯å¿ èŠã§ããïŒã
第10ç« ïŒãµããªã¡ã³ã被害ããã®å埩
èæ©èœå埩ãžã®éã®ã
å埩æéã®ç®å®
軜床ïŒAST/ALT 100以äžïŒïŒ1-3ã¶æ
äžç床ïŒAST/ALT 100-500ïŒïŒ3-6ã¶æ
é床ïŒAST/ALT 500以äžïŒïŒ6-12ã¶æ
è硬å€ã«è³ã£ãå ŽåïŒå埩å°é£
å埩ãä¿é²ããçæŽ»ç¿æ £
é£äºçæ³
ã¿ã³ãã¯è³ªïŒäœé1kgããã1.2-1.5g
åå²éã¢ããé žïŒBCAAïŒã®æå
äºéã®è£å ïŒç¡è £ãã¬ããŒãªã©ïŒ
ã¢ã«ã³ãŒã«å®å šçŠæ¢
éåçæ³
æé žçŽ éåïŒé±150å以äž
çåãã¬ãŒãã³ã°ïŒé±2-3å
ãšã¬ã倪極æ³ãªã©ã®è»œéå
ç¡ç æ¹å
7-8æéã®ç¡ç 確ä¿
22æ-2æã®ãŽãŒã«ãã³ã¿ã€ã éèŠ
æŒå¯ã¯30å以å
被害è ã®äŒã𿝿Žå¶åºŠ
å°æè£œè¬è¢«å®³è ã®äŒ
äŒå¡æ°ïŒ423åïŒ2024幎12æçŸåšïŒ
éå£èšŽèšæºåäž
ç¡ææ³åŸçžè«å®æœ
æ¶è²»è åºã®ææžå¶åºŠ
æ¶è²»è ãããã©ã€ã³ïŒ188
PIO-NETïŒå šåœæ¶è²»ç掻æ å ±ãããã¯ãŒã¯ã·ã¹ãã ïŒ
ADRïŒè£å€å€çŽäºè§£æ±ºæç¶ïŒ
å»çè²»ã®è£å©
å»è¬åå¯äœçšè¢«å®³ææžå¶åºŠïŒãµããªã¯å¯Ÿè±¡å€ã ãåèã«ïŒ
é«é¡çé€è²»å¶åºŠã®æŽ»çš
å·ç æåœéïŒäŒç€Ÿå¡ã®å ŽåïŒ
第11ç« ïŒ2025幎以éã®å±æ
èŠå¶åŒ·åã®åã
æ¶è²»è åºã®æ°æ¹éïŒ2024幎7æçºè¡šïŒ
æ©èœæ§è¡šç€ºé£åã®äºåŸãã§ãã¯åŒ·å
AI掻çšã«ããå šæ°èª¿æ»
èåœè¡šç€ºãžã®çœ°å匷åïŒèª²åŸŽé3%â10%ïŒ
æå®³äºè±¡å ±åã®çŸ©å忀èš
2026幎æœè¡ç®æš
é»åã·ã¹ãã ã«ããå³æå ±å
åææã®ãã¬ãŒãµããªãã£
ãããã¯ãã§ãŒã³æè¡ã®æŽ»çš
2027幎å®å šå®æœäºå®
æ°æè¡ã«ããå®å šæ§åäž
éºäŒåæ€æ»ã®æ®å
CYP2C19éºäŒåæ€æ»ïŒ1äžå以äžã«
HLAéºäŒåæ€æ»ïŒä¿éºé©çšæ€èšäž
åå¥åãµããªã¡ã³ãåŠæ¹ã®å®çŸ
AI ã«ããå¯äœçšäºæž¬
å人ã®éºäŒæ å ±ãç æŽãæè¬æŽããå¯äœçšãªã¹ã¯ãäºæž¬
粟床90%以äžãéæïŒ2024幎æ±å€§ç ç©¶ïŒ
代æ¿å»çã®å¯èœæ§
é£äºçæ³ã®èŠçŽã
å°äžæµ·é£ïŒå¿è¡ç®¡çŸæ£ãªã¹ã¯30%æžå°
åé£ïŒããæ»äº¡ç20%æžå°
ãã©ã³ãããŒã¹ïŒç³å°¿ç ãªã¹ã¯23%æžå°
éååŠæ¹ã®ç¢ºç«
éåã¯ãè¬ããšããŠåŠæ¹ããæä»£ãž
çŸæ£å¥éåããã°ã©ã ã®ä¿éºé©çš
ãã€ã³ããã«ãã¹ã®å»çå¿çš
ã¹ãã¬ã¹é¢é£çŸæ£ã®æ¹å
æ ¢æ§çŒçã®è»œæž
å ç«æ©èœã®åäž
第12ç« ïŒä»æ¥ããã§ããèèãå®ã10ã®ç¿æ £
1. ãµããªã¡ã³ãææšé¢
ãŸãæšãŠãã¹ããµããª
éå°ãã1幎以äžçµéãããã®
æå衚瀺ãäžæç¢ºãªãã®
æµ·å€ããåäººèŒžå ¥ãããã®
广ãæããªããã®
2. æ°Žã1æ¥2ãªããã«é£²ã
èèã®è§£æ¯æ©èœãå©ããæãã·ã³ãã«ã§å¹æçãªæ¹æ³ã
3. 22æã«ã¯å¯ã
æé·ãã«ã¢ã³ã®åæ³ããŒã¯ã«åãããè现èã®ä¿®åŸ©ãä¿é²ã
4. é±3åã30åæ©ã
æé žçŽ éåã«ããèèã®èèªèç©ãé²ããè¡æµãæ¹åã
5. çºé µé£åãæ¯æ¥é£ã¹ã
çŽè±ãå³åããšãŒã°ã«ããªã©ã§è žå ç°å¢ãæŽããèèã®è² æ ã軜æžã
6. ã¢ã«ã³ãŒã«ã¯é±2æ¥ãŸã§
äŒèæ¥ãèšããè现èã®åçãä¿ãã
7. ç³è³ªãæ§ããã«
éå°ãªç³è³ªã¯èèªèã®åå ãçœç±³ãçç±³ã«å€ããã ãã§ã广çã
8. æ·±åŒåžã1æ¥10å
ã¹ãã¬ã¹ã¯èæ©èœãäœäžããããæ·±åŒåžã§å¯äº€æç¥çµã掻æ§åã
9. äœéã5%æžãã
è¥æºã¯èèã«æãæªåœ±é¿ã5%ã®æžéã§èæ©èœã¯åçã«æ¹åã
10. 幎2åã®è¡æ¶²æ€æ»
æ©æçºèŠãäœããéèŠãèªèŠçç¶ãåºãåã«å¯ŸåŠãã
çµç« ïŒãµããªã¡ã³ãã«é Œããªããæ¬åœã®å¥åº·ãšã¯
ããå»åž«ã®åçœ
ãç§ã¯èèå°éå»ãšããŠã20幎éã§1,000人以äžã®ãµããªã¡ã³ãæ§èé害ã蚺ãŠããŸããããã®å€ããããå¥åº·ã«ãªãããããšããçŽç²ãªæãããå§ãŸã£ãŠããŸããã
ããããå¥åº·ã¯é å€ãã«ãã»ã«ã®äžã«ã¯ãããŸããã
æ¯æ¥ã®é£äºãé©åºŠãªéåãååãªç¡ç ãã¹ãã¬ã¹ã®ç®¡çã人ãšã®ã€ãªããããããã®åºæ¬çãªããšã®ç©ã¿éãããããæ¬åœã®å¥åº·ãäœãã®ã§ãã
ãµããªã¡ã³ãã¯ããããŸã§ããè£å©ãã䞻圹ã§ã¯ãããŸããã
ãããããªããä»ãäœçš®é¡ãã®ãµããªã¡ã³ãã飲ãã§ãããªããäžåºŠç«ã¡æ¢ãŸã£ãŠèããŠã¿ãŠãã ããã
æ¬åœã«å¿ èŠã§ããïŒ
å»åž«ã«çžè«ããŸãããïŒ
äœèª¿ã¯è¯ããªã£ãŠããŸããïŒ
çããããããããªããåæ°ãæã£ãŠãããããšããå¥åº·ãžã®ç¬¬äžæ©ã§ãã
4,786äžäººãžã®ç·æ¥ã¡ãã»ãŒãž
æ¥æ¬ã®ãµããªã¡ã³ãå©çšè 4,786äžäººã®çããã
ä»ãããªãã®èèã¯æ²é³ŽãäžããŠãããããããŸããã
ã§ãããŸã é ããããŸããã
仿¥ããããµããªã¡ã³ããšã®ä»ãåãæ¹ãèŠçŽããŸãããã
å¿ èŠãªã®ã¯ãé«äŸ¡ãªãµããªã¡ã³ãã§ã¯ãªããåœããåã®çæŽ»ç¿æ £ã
é£äºã倧åã«ãã ã³ã³ããåŒåœã§ã¯ãªããèªçãã ãµããªã¡ã³ãã§ã¯ãªããéèãã
äœãåãã ãšã¬ããŒã¿ãŒã§ã¯ãªããéæ®µãã è»ã§ã¯ãªããæ©ããã
å¿ãäŒãã ã¹ããã§ã¯ãªããæ¬ãã SNSã§ã¯ãªãã察話ãã
èªç¶ãšã€ãªãã 宀å ã§ã¯ãªããå±å€ãã 人工ã§ã¯ãªãã倩ç¶ãã
ãããã¯ãã©ããªé«äŸ¡ãªãµããªã¡ã³ãããããããªãã®å¥åº·ã«è²¢ç®ããŸãã
æåŸã«ïŒéžæã¯ããªã次第
ãã®èšäºãèªã¿çµããä»ãããªãã«ã¯2ã€ã®éžæè¢ããããŸãã
éžæè¢1ïŒäœãå€ããªã
ä»ãŸã§éããµããªã¡ã³ãã飲ã¿ç¶ãããã€ãæ¥ããããããªãå¥åº·è¢«å®³ã®ãªã¹ã¯ãåãå
¥ããã
éžæè¢2ïŒä»æ¥ããå€ãã
ãµããªã¡ã³ããèŠçŽããæ¬åœã«å¿
èŠãªãã®ã ããæ®ããåºæ¬çãªçæŽ»ç¿æ
£ã®æ¹åã«åãçµãã
ã©ã¡ããéžã¶ãã¯ãããªã次第ã§ãã
ããããèŠããŠãããŠãã ããã
èèã¯æ²é»ã®èåšã
çç¶ãåºãæã«ã¯ããã§ã«æé ããããããŸããã
å°æè£œè¬ã®è¢«å®³è ã®æ¹ã ãããŸããèªåã...ãšæã£ãŠããã¯ãã§ãã
ãå¥åº·ã«ãªãããã
ãã®çŽç²ãªæãããéã«å¥åº·ã奪ãããšãããã
ãããããµããªã¡ã³ã倧åœã»æ¥æ¬ã®çŸå®ã§ãã
ã§ããç¥èãããã°é²ããŸãã
æ£ããæ å ±ãããã°ãèªåãšå®¶æãå®ããŸãã
ãã®èšäºããããªããšããªãã®å€§åãªäººã®å¥åº·ãå®ãäžå©ãšãªãããšããå¿ããé¡ã£ãŠããŸãã
ããªãã®èèãããµããªã¡ã³ãããå®ãããã«ã
仿¥ããå€åã®ç¬¬äžæ©ã§ãã
åèè³æã»æ å ±æº
æ¥æ¬èèåŠäŒãè¬ç©æ§èé害蚺çã¬ã€ãã©ã€ã³2024ã
åçåŽåçãå¥åº·é£åã«ããå¥åº·è¢«å®³æ å ±ã
åœç«å¥åº·ã»æ é€ç ç©¶æãå¥åº·é£åã®å®å šæ§ã»æå¹æ§ããŒã¿ããŒã¹ã
æ¶è²»è åºãæ©èœæ§è¡šç€ºé£åå¶åºŠã«ã€ããŠã
WHOãTraditional Medicine Strategy 2025-2034ã
FDAãDietary Supplement Health and Education Actã
å°æè£œè¬æ ªåŒäŒç€ŸãçŽ éº¹é¢é£è£œåå¥åº·è¢«å®³ã«é¢ããå ±åæžã
æ¥æ¬æ¶ååšç åŠäŒããµããªã¡ã³ãé¢é£èéå®³å šåœèª¿æ»ã
Drug-Induced Liver Injury Network (DILIN) Registry
European Association for the Study of the Liver (EASL) Guidelines
ãã®èšäºã¯ãå ¬éãããŠããåŠè¡è«æãæ¿åºæ©é¢ã®å ±åæžãå»åŠäŒã®ã¬ã€ãã©ã€ã³çãåºã«äœæãããŠããŸããåå¥ã®å¥åº·çžè«ã«ã€ããŠã¯ãå¿ ãå»çæ©é¢ãå蚺ããå°éå»ã®èšºæãåããŠãã ããã
æåŸãŸã§èªãã§é ãããããšãããããŸãïŒ
ä»ã«æ°ã«ãªãèšäºããã£ããæ¯éãã§ãã¯ããŠã¿ãŠäžããã
ããªãã«ãšã£ãŠã®å¹žãã¬ã·ãæã£ãŠããŸãã
幞ãã¬ã·ãïœãµã€ãããããªã³ã¯
- #æ¯æ¥note
- #note
- #æ¯æ¥æçš¿
- #noteæ¯æ¥æŽæ°
- #äºé²å»åŠ
- #æ©èœæ§è¡šç€ºé£å
- #å¥åº·è¢«å®³
- #éå°æå
- #å¥åº·ãªãã©ã·ãŒ
- #èèã±ã¢
- #æ¶è²»è 被害
- #çŽ éº¹ãµããª
- #æ¥æ¬äººã®äœè³ª
- #èæ©èœæ€æ»
- #è¬ç©æ§èé害
- #èèé害
- #å»è¬åå¯äœçš
- #ALTäžæ
- #CYP2C19éºäŒå
- #ãµããªã¡ã³ã被害
- #å¥åº·é£åã®å±éºæ§
- #å°æè£œè¬åé¡
- #ASTç°åžžå€
- #ãµããªã¡ã³ãèŠå¶